Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

BioTenCer: Biofeedback as Preventive Treatment in Tension Type Headache

NCT: NCT07136740 · RECRUITING

NCT IDNCT07136740
StatusRECRUITING
Start Date2025-10-17
Completion2027-12
SponsorHelse Nord-Trøndelag HF (OTHER)
First posted
Last updated

Brief Summary

The purpose of this study is to test a therapist-independent home-based smartphone app-based biofeedback treatment in adults with tension type headache. The aim of the study is to assess the safety and performance of the Cerebri-TTH biofeedback device as a preventive treatment in adults with frequent and chronic tension type headache. The primary endpoint of the study is the change in the mean Area-Under-the-headache-Curve (AUC) from baseline to the last 28-day period during the treatment phase, in the treatment group as compared to the placebo group.

Frequently Asked Questions

What is BioTenCer: Biofeedback as Preventive Treatment in Tension Type Headache?

BioTenCer: Biofeedback as Preventive Treatment in Tension Type Headache is a clinical trial registered under NCT07136740. Current status: RECRUITING.

What is the status of NCT07136740?

The current status of NCT07136740 (BioTenCer: Biofeedback as Preventive Treatment in Tension Type Headache) is: RECRUITING.

When did BioTenCer: Biofeedback as Preventive Treatment in Tension Type Headache start?

BioTenCer: Biofeedback as Preventive Treatment in Tension Type Headache started on 2025-10-17.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.